CLEARPOINT NEURO INC (CLPT)
Sector: Health Care
2026 Annual Meeting Analysis
CLEARPOINT NEURO INC · Meeting: May 20, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
CEO and director since November 2017; the 3-year stock return of +1.2% outperforms the IHI (iShares US Medical Devices ETF) 3-year return of -1.0% by +2.2 percentage points, well below the 50-percentage-point underperformance threshold required to trigger a vote against, and no overboarding, attendance, or independence concerns apply.
Board chairman since May 2017 with relevant healthcare and medical device experience; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) is +2.2 percentage points in the company's favor, far short of the 50-percentage-point threshold, and no overboarding or attendance issues are disclosed.
Director since July 2021 with extensive legal, financial, and corporate governance experience; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) does not trigger the underperformance threshold, and no overboarding or attendance concerns are disclosed.
Director since September 2019 with deep medtech and venture capital experience; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) is positive and well within policy limits, and no overboarding or attendance issues are disclosed.
Director since April 2020 with medical and biopharmaceutical leadership experience; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) does not trigger the underperformance threshold, and no overboarding or attendance concerns are noted — he holds one outside public board seat as a sitting CEO at PTC Therapeutics, which is within the one-seat limit for sitting CEOs.
Director since November 2021 with distinguished neurosurgery and academic expertise highly relevant to ClearPoint's business; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) is positive and no overboarding or attendance concerns are disclosed.
Director since March 2014 with broad commercial and operational leadership experience in medical devices; the 3-year TSR gap versus IHI (iShares US Medical Devices ETF) is +2.2 percentage points in the company's favor, well below the 50-percentage-point threshold needed to trigger a vote against.
All seven director nominees pass the policy screens — the company's 3-year stock return of +1.2% outperforms the IHI (iShares US Medical Devices ETF) benchmark by +2.2 percentage points, well within the 50-percentage-point tolerance for the low-positive TSR tier, no director is overboarded, all met the 75% attendance threshold in 2025, no independence concerns or familial relationships with management are disclosed, and the slate brings relevant healthcare, medical device, financial, and legal expertise.
Say on Pay
✓ FORCEO
Joseph M. Burnett
Total Comp
$2,814,944
Prior Support
96%%
The CEO's total reported compensation of $2,814,944 is reasonable for a CEO at a roughly $258 million medical device company, and last year's say-on-pay vote received overwhelming 96% support, indicating strong shareholder satisfaction with the program. Pay mix is appropriately weighted toward variable compensation — base salary of $584,231 represents approximately 21% of total pay, well within the 40% fixed-pay limit, with the majority coming from stock awards and performance-based bonuses. Although the company missed its formulaic bonus target (paying out at 78% rather than the formula-driven 55%) by exercising upward discretion, the overall pay level does not appear to exceed benchmark thresholds and the 3-year stock return modestly outperformed the IHI (iShares US Medical Devices ETF) benchmark, so pay-for-performance alignment is not a concern.
Auditor Ratification
✓ FORAuditor
Cherry Bekaert LLP
Tenure
N/A
Audit Fees
$313,345
Non-Audit Fees
$33,606
The non-audit fees paid to Cherry Bekaert LLP in 2025 were $33,606 against audit fees of $313,345, giving a non-audit ratio of approximately 11% — well below the 50% threshold that would raise independence concerns; auditor tenure is not explicitly disclosed in the proxy so no tenure trigger fires; and the company's market cap of approximately $258 million is within the range where a large national or regional firm is considered appropriate under policy.
Overall Assessment
The 2026 ClearPoint Neuro annual meeting presents a clean ballot: all seven director nominees receive FOR votes as the company's 3-year stock performance modestly outperforms the IHI (iShares US Medical Devices ETF) benchmark and no governance red flags are present, the auditor ratification passes with a very low non-audit fee ratio of approximately 11%, and say-on-pay receives a FOR vote supported by last year's 96% shareholder approval and a pay structure where fixed salary is only about 21% of the CEO's total compensation. The equity plan share increase in Proposal 4 is outside the scope of this policy version and no determination is made on that item.